Cell transplantation models / MDA-MB-231
Triple-negative breast cancer
Classic human TNBC line; common routes in immunodeficient mice include orthotopic fat pad, subcutaneous, tail-vein lung, intracardiac/intratibial bone, and brain mets (RUO).
SKU: MC-h133 · Disease models · In-vitro spheroid
Orthotopic engraftment of human TNBC line MDA-MB-231 (MC-h133) into the #4 mammary fat pad of immunodeficient mice. Written as a novice pack (BOM, timeline, recipe, surgery checks) from the literature—not a substitute for IACUC or surgical training.
Open full protocol →
Flank s.c. MDA-MB-231 as a caliper-friendly ectopic CDX for early antitumor efficacy. Not a primary metastasis model (s.c. xenografts often fail to metastasize vs orthotopic), but occasional co-graft papers still report early spread—tagged weak, not absolutely non-metastatic.
Open full protocol →
Tail-vein MDA-MB-231 (often Luc-labeled) bypasses primary growth/intravasation to score circulating survival, extravasation, and lung colonization. Lung-tropic LM2 optional. Written as a novice pack—not a substitute for IACUC or injection training.
Open full protocol →
Left-ventricular MDA-MB-231 (or BO/B02) seeds experimental osteolysis. Parental hits bone at 3–4 weeks ± adrenal/ovary/brain; BO is nearly bone-only. Written as a JoVE novice pack—not a substitute for surgical training.
Open full protocol →
2.5×10⁵ cells in 10 μL into proximal tibial marrow models established osteolysis and tumor–bone crosstalk without homing. Contralateral PBS sham. Watch JoVE—not a substitute for surgical training.
Open full protocol →
Default is 231-BR LV (Yoneda 1×10⁵ or Zhou ~1.75–2×10⁵ / 100 μL) for multifocal brain mets. Carotid follows Liu PDX technique (1×10⁵ / 50 μL)—not an MDA-231 default dose. Intracranial 1–2 μL scores local growth only. Watch JoVE—not a substitute for surgical training.
Open full protocol →
After #4 fat-pad orthotopic take (technique on the orthotopic page), follow long-term or resect the primary at >300 mm³ and track spontaneous lung/node mets. Covers intravasation; slower than tail vein. Parental rarely seeds bone spontaneously in nude/NOD-SCID. Not a substitute for surgical training.
Open full protocol →
Red [Non-metastatic] = local tumorigenesis, not a distant-met endpoint; [Weak metastasis evidence] = poorly supported for parental line—exploratory/negative-control use.